P0782Cardiovascular risk factors and inflammation in unselected Italian IBD outpatients: a real life analysis from a multicenter study on > 1,200 patients

Background The prevalence of cardiovascular (CV) risk factors in IBD patients is not well known. Inflammation may act as an additional independent CV risk factors, and an increased CV risk should be carefully considered in the therapeutic decision making. Aim of this study is to explore the prevalence of CV risk factors in an unselected Italian IBD outpatient population. Methods Within a cross-sectional perspective observational study approved by Ethical Committee (ref. 124/2024) we recruited consecutive IBD outpatient attending 13 Gastroenterology Units in Italy between November 2024 and August 2025. Their personal and familiar CV risk factors, along with clinical features (disease activity and characteristics) and blood test results were prospectively collected. Individual CV risk factors prevalence and combination of risk factors with SCORE2 /SCORE2-OP algorithms1,2 were the main goals of data analysis. Results 1,215 IBD patients were enrolled; Crohn’s disease and ulcerative colitis/IBDU cases were equally represented (616 and 599, respectively), overall 233 cases (19.2%) reported clinically active disease at the observation. Familial history of major CV events was positive in 334 (27.5%) cases, while 95 (7.8%) patients had a personal history of previous CV events (cardiac ischaemic or thromboembolic disorders or atrial fibrillation). Total cholesterol levels above 190 mg/dl were observed in 479/1,194 cases (39.6%), with critically elevated LDL-cholesterol (>130 mg/l) in 263 (23.7%) of cases. Complete data for SCORE2 calculation were available for 1,034 cases without personal history of CV events. According to SCORE2 classification for the cardiovascular risk, with age stratifications, risk resulted low for 738 (71.4%), intermediate for 220 (21.3%), and elevated in 76 (7.4%) cases, respectively (Figure 1). The distribution of patients with clinically active disease was not significantly different in the 3 risk groups: 19.3% in low, 15.2% in intermediate, and 16.7 in elevated risk patients, respectively (p = 0.313). The number of cases 0 or 1 CV risk factor was uniformly reduced by 23-30% in all groups, when adding clinical activity as an additive risk factor. Clinical covariates association to risk classes is reported in Table 1. Conclusion Cardiovascular risk factors and positive personal history of CV events are quite common in this large Italian IBD population, and inflammation may act as further risk factor, relevant in 1/5 of cases. Patients’evaluation should carefully consider CV risk factors in order to best avoid unintentional hazards for their health and to best address every treatment risk/benefit balance. References: 1. SCORE2 working group and ESC Cardiovascular risk collaboration et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 42, 2439–2454 (2021) 2. SCORE2-OP working group and ESC Cardiovascular risk collaboration et al. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J. 42, 2455–2467 (2021) Conflict of interest: Di Giorgio, Francesca Maria: No conflict of interest Carboni, Edoardo: No conflict of interest Bracciamà, Emanuele: No conflict of interest Cafasso, Carla: No conflict of interest Simondi, Daniele: No conflict of interest Adriani, Alessandro: No conflict of interest Mangia, Michela: No conflict of interest Saettone, Silvia: No conflict of interest Penati, Chiara M.: none Bodini, Giorgia: No conflict of interest Comi, Giovanni: No conflict of interest Reggiani, Stefania: No conflict of interest Martini, Sabina: No conflict of interest Serra, Anna Maria: No conflict of interest Papandrea, Maria: No conflict of interest Sani, Saeed: No conflict of interest Stalla, Francesco Maria: Guest to courses or conventions ▪ Giuliani s.p.a. ▪ Johnson & Johnson ▪ Takeda ▪ Abbvie ▪ Boston Scientific ▪ Pentax ▪ CadiGroup Presenter to courses or conventions ▪ Takeda Lavagna, Alessandro: No conflict of interest Mendolaro, Marco: None Bianchi, Francesca: No conflict of interest Pagano, Nico: No conflict of interest Battaglia, Edda: No conflict of interest Pulitanò, Raffaella: No conflict of interest Ribaldone, Davide Giuseppe: No conflict of interest Cappello, Maria: No conflict of interest Rocca, Rodolfo: No conflict of interest Dr. Daperno, Marco: Personal Fees:Takeda, Johnson & Johnson, GILEAD, Roche, Pfizer, Abbvie, Ferring, Chiesi, Alfasigma, Celltrion, Sanofi. Clinical trials: Takeda, Janssen, Roche